Literature DB >> 34363610

Rodent models of hypertension.

Hamdi A Jama1,2, Rikeish R Muralitharan1,3, Chudan Xu1, Joanne A O'Donnell1, Mariane Bertagnolli4,5, Bradley R S Broughton6, Geoffrey A Head6,7, Francine Z Marques1,2.   

Abstract

Elevated blood pressure (BP), or hypertension, is the main risk factor for cardiovascular disease. As a multifactorial and systemic disease that involves multiple organs and systems, hypertension remains a challenging disease to study. Models of hypertension are invaluable to support the discovery of the specific genetic, cellular and molecular mechanisms underlying essential hypertension, as well as to test new possible treatments to lower BP. Rodent models have proven to be an invaluable tool for advancing the field. In this review, we discuss the strengths and weaknesses of rodent models of hypertension through a systems approach. We highlight the ways how target organs and systems including the kidneys, vasculature, the sympathetic nervous system (SNS), immune system and the gut microbiota influence BP in each rodent model. We also discuss often overlooked hypertensive conditions such as pulmonary hypertension and hypertensive-pregnancy disorders, providing an important resource for researchers. LINKED ARTICLES: This article is part of a themed issue on Preclinical Models for Cardiovascular disease research (BJP 75th Anniversary). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.5/issuetoc.
© 2021 The British Pharmacological Society.

Entities:  

Keywords:  Ang II; DOCA; SHR; inflammation; microbiome; salt

Mesh:

Year:  2021        PMID: 34363610     DOI: 10.1111/bph.15650

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  6 in total

1.  Puerarin-V prevents the progression of hypoxia- and monocrotaline-induced pulmonary hypertension in rodent models.

Authors:  Di Chen; Hui-Fang Zhang; Tian-Yi Yuan; Shu-Chan Sun; Ran-Ran Wang; Shou-Bao Wang; Lian-Hua Fang; Yang Lyu; Guan-Hua Du
Journal:  Acta Pharmacol Sin       Date:  2022-02-21       Impact factor: 7.169

Review 2.  Cross-Talk between the (Endo)Cannabinoid and Renin-Angiotensin Systems: Basic Evidence and Potential Therapeutic Significance.

Authors:  Krzysztof Mińczuk; Marta Baranowska-Kuczko; Anna Krzyżewska; Eberhard Schlicker; Barbara Malinowska
Journal:  Int J Mol Sci       Date:  2022-06-06       Impact factor: 6.208

3.  Effects of the peripheral CB1 receptor antagonist JD5037 in mono- and polytherapy with the AMPK activator metformin in a monocrotaline-induced rat model of pulmonary hypertension.

Authors:  Patryk Remiszewski; Anna Pędzińska-Betiuk; Krzysztof Mińczuk; Eberhard Schlicker; Justyna Klimek; Janusz Dzięcioł; Barbara Malinowska
Journal:  Front Pharmacol       Date:  2022-09-02       Impact factor: 5.988

Review 4.  Left Atrial Myocardium in Arterial Hypertension.

Authors:  Jens Kockskämper; Florentina Pluteanu
Journal:  Cells       Date:  2022-10-08       Impact factor: 7.666

Review 5.  Vascular smooth muscle ion channels in essential hypertension.

Authors:  Nuria Daghbouche-Rubio; José Ramón López-López; María Teresa Pérez-García; Pilar Cidad
Journal:  Front Physiol       Date:  2022-09-23       Impact factor: 4.755

Review 6.  Control of aging by the renin-angiotensin system: a review of C. elegans, Drosophila, and mammals.

Authors:  Brian M Egan; Andrea Scharf; Franziska Pohl; Kerry Kornfeld
Journal:  Front Pharmacol       Date:  2022-09-14       Impact factor: 5.988

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.